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Abstract
Background: Staphylococcus aureus (S. aureus) is the most common pathogen responsible for osteomyelitis.
Objectives: Our objective was to investigate the potential of a probiotic as a treatment for S. aureus-induced infection following
fracture fixation in a rat model.
Methods: Fifty male Sprague-Dawley rats were assigned to five groups (Control, S. aureus, S. aureus +ceftriaxone, S. aureus + once
weekly probiotic, and S. aureus+ twice weekly probiotic). Lactobacillus casei subsp. casei (ATCC: 39392) was selected from eight strains
of probiotic bacteria with anti-staphylococcal activity. Infection was induced by inoculation with106 colony-forming units (CFU) of
S. aureus in a closed femur fracture model stabilized with an intramedullary pin. Three weeks after the surgery, the development of
infection and response to the therapy was documented using radiographs, microbiological and histopathological analysis.
Results: No bacteria were recovered from rats in the Control group. The analysis of variance revealed a significant difference in the
CFU/femur (P < 0.001) and CFU/pin (P = 0.001) across all five treatment groups. When the results were compared, the CFU/femur was
significantly lower in the S. aureus + Probiotic twice weekly in comparison with S. aureus (P = 0.008) and the S. aureus + ceftriaxone
(P = 0.012) groups. Repeated measure ANOVA to test the radiographic scores during the follow-up time between the intervention
groups revealed no significant differences (P = 0.179).
Conclusions: Parenteral administration of viable L. casei inhibits S. aureus-induced infection as shown by the bacteriologic anal-
ysis, but makes no difference to the radiological union rates. This could be the first step towards developing an effective, biologic
adjunctive therapy for the management of osteomyelitis following fracture fixation.
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1. Background
Osteomyelitis is an inflammatory process of bone with
resultant destructive and necrotic change accompanied
by new bone formation, which can progress to a chronic
or persistent stage (1). The incidence of osteomyelitis dif-
fers according to the primary inoculation and the under-
lying disease with a range of 1% to 15% (2, 3). Rubin eval-
uated 1,351,362 non-obstetric hospital discharges in New
York city hospitals in 1995 and showed that an estimated
2000 (0.00147) were patients with S. aureus osteomyelitis
with an average hospital stay estimated to be 23.9 days with
subsequent incurred costs of 35000 dollars indicating a
significant burden to the health economy (4). S. aureus
is the most common pathogen responsible for both acute
and chronic forms of osteomyelitis (1, 5, 6). S. aureus has
developed a plethora of strategies to evade the host innate
and adaptive immune systems, with a high resistance to
different therapeutic options (7). Tice et al. in a long-term
follow-up study of osteomyelitis treated in the outpatient
setting found that 31% of 452 patients had recurrent infec-
tion, most within one year of occurrence (8).
Stengel et al. in a systematic review with meta-analysis
of antibiotic therapy for osteomyelitis reported that the
penetration of an antibiotic agent into an infected bone is
determined by the pharmacological characteristics of the
drug, degree of vascularization, soft-tissue coverage and
the presence of a foreign body (9). To overcome the lim-
ited penetration of the systemic agents into poorly vascu-
larized bone, systems for local delivery of antibiotics have
been implemented in the previous studies (10, 11). Bucholz
and Engelbrecht introduced the delivery of high-dose an-
tibiotics to the skeletal tissues by resin (Palacos) in 1970
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(12). Bone cement (13, 14) and polymethylmethacrylate
(PMMA) beads (15) are other skeletal drug-delivery systems
commonly used for this purpose. However, all of these
techniques are static in nature with the potential of bac-
terial resistance.
Probiotics are viable cell preparations that have bene-
ficial effects (16). Different strains of probiotics have dif-
ferent strategies to compete with S. aureus. Probiotic has
been used in the treatment of many clinical infections
in the middle ear, bladder, gut and the vagina of the hu-
mans and in the wounds of the animals (17-20). Since some
probiotics are a dynamic source of antimicrobial agent
with variable strategy, we hypothesized that specific pro-
biotic strains of lactobacilli with predefined anti-infective
properties against S. aureus could inhibit S. aureus-induced
osteomyelitis. We, therefore, implemented an infection
model following trauma fixation and investigated the ther-
apeutic potential of the probiotics. A successful therapeu-
tic strategy at this stage of trauma comprising an infected
fracture with metalwork in situ would prevent the further
development of infection in critically ill patients and allow
the retention of fixation until osseous union occurs.
2. Methods
2.1. Study Design
Fifty male Sprague-Dawley rats were assigned to five
groups:
Control (pinned femur fracture + 0.1 mL Phosphate
buffered saline (PBS))
S. aureus (pinned femur fracture + 0.1 mL of S. aureus)
S. aureus +ceftriaxone (pinned femur fracture + 0.1 mL
of S. aureus + ceftriaxone (50 mg/kg) every 24 hours for 3
weeks)
S. aureus + once weekly probiotic (pinned femur frac-
ture + 0.1 mL of S. aureus + 0.1 mL Lactobacillus (LAD) every
week for three weeks)
S. aureus + twice weekly probiotic (pinned femur frac-
ture + 0.1 mL of S. aureus+ 0.1 mL LAD twice weekly for three
weeks)
The rats were humanely euthanized three weeks af-
ter the surgery with a lethal dose of Xylazine. The de-
velopment of osteomyelitis was documented using radio-
graphs (all animals), postmortem microbiological (n = 8
per group) and histopathological (n = 1 per group) analy-
sis. The study protocol was approved by the **** animal care
and use committee (date of approval: 29.1.2010, Code num-
ber: 16).
2.2. Bacterial Preparation
2.2.1. Bacterial Strains
Eight strains of LAD and five strains of staphylococcus
were purchased from the Iranian research organization
for science and technology (IROST). These strains were se-
lected due to their potential effect against S. aureus in the
previous studies (18, 21-25).
2.2.2. Antimicrobial Activity
The antibiotic susceptibility of all isolated strains was
tested based on the standard methodology recommended
by the Canadian committee on antibiotic resistance (26). A
modified Coconnier model (27) was used to assess the an-
tibacterial activity of each LAD with a modified “spot on the
lawn” method described by Navarro (28). Based on the an-
tibacterial activity of each LAD, Lactobacillus casei subsp. ca-
sei (ATCC: 39392) was the most potent probiotic against S.
aureus, subsp. aureus (ATCC: 33591) and was selected for the
rest of the study.
2.3. Surgical Procedure
The surgical procedure was a modification of that out-
lined in detail by Skott et al. (29). Each rat was anes-
thetized using intraperitoneal injections of ketamine (100
- 200 mg/kg) and xylazine (2.0 - 4.0 mg/kg). The right fe-
mur was prepared aseptically and a 20-gauge needle was
used to create an entry port into the distal aspect of the
medullary canal of the femur which was reamed to allow
the insertion of the intramedullary pin. An inoculation
dose of 0.1 mL of staphylococcus suspension (106 bacteria)
was slowly injected into the medullary cavity in the exper-
imental groups, and in the control group PBS was injected
instead.
A sterile stainless steel Kirschner wire, 1 mm in di-
ameter and 20 mm in length was then inserted into the
medullary canal and seated in the cortical bone in the prox-
imal aspect of the femur. Thereafter, a mid-shaft closed
fracture of the right femur was created using a specifi-
cally designed fracture apparatus that consisted of a blade
which was placed in contact with the femur to fracture the
femoral cortex before rotating the femur and fracturing
the remainder of the cortex.
2.4. Treatment Procedure
We defined two time intervals for the probiotic injec-
tion to assess the dose-response effect. Rats in the S. aureus
+ probiotic group received 0.1 mL Lactobacillus casei subsp.
casei (106 CFU in 0.1 mL) once or twice weekly starting 24
hours after the inoculation, via two sub-periosteal injec-
tions near the fracture site for the duration of the study
(three weeks). The S. aureus + ceftriaxone group received
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ceftriaxone (50 mg/kg) every 24 hours, starting 4 hours af-
ter the inoculation, via a subcutaneous injection for the du-
ration of the study.
2.5. Radiographic Assessment of Osteomyelitis
Lateral radiographs of the right hind limb were ob-
tained at weeks one, two, and three postoperatively. Two
individuals (BS, CH) evaluated the radiographs focusing on
three regions of interest (RoI):
(1) Proximal metaphyseal area
(2) Diaphyseal region involving the site of the fracture
(3) Distal metaphyseal area
Each radiograph was assessed based on a validated sys-
tem used by Lucke et al. (30, 31). The following radiographic
changes were estimated for each ROI: (1) osteolysis, (2) soft
tissue swelling, (3) periosteal reaction, (4) general impres-
sion and (5) deformity. The changes were given a score cor-
responding to the following scale: 0 - absent, 1 - mild, 2 -
moderate, or 3 - severe. For the general impression evalua-
tion, a 0 represented a normal appearing femur/fracture
and 3 represented severe changes present overall. In ad-
dition, sequestra formation (6) and spontaneous fracture
(7) were evaluated for each femur as a whole and were
awarded a score of 0 - absent or 1 - present. The scores were
then summated with the highest possible total score being
47. The mean scores from the two evaluators were used for
the statistical evaluation.
2.6. Recovery of Bacteria
Three weeks after the surgery, the femora of the right
hind legs were dissected free from the underlying tissue
under sterile conditions. The K-wires were aseptically re-
trieved from the operated femora prior to the snap freez-
ing. Under sterile conditions, the K-wires were placed in
2.0 mL of sterile PBS, then spun for five minutes and cen-
trifuged (10,000 RPM for 10 seconds) to dislodge adher-
ent bacteria. A hundred micro liter samples were then col-
lected for the microtiter dilution and the results were used
to calculate the CFU/pin.
Each femur was snap frozen and ground to powder un-
der sterile conditions. A hundred and fifty milligrams of
the bone powder was agitated in 1.5 mL of sterile PBS for
2 minutes by vortex (3000 RPM) and the suspension was
centrifuged for 10 seconds (10,000 RPM). A hundred mi-
croliters of the supernatant was withdrawn for serial dilu-
tion and sampled for microtiter dilutions to calculate the
CFU/femur.
2.7. Microtiter Dilution and Viable Bacterial Counts
The CFU was determined in quadruplicate by collect-
ing an aseptic sample. Tenfold dilutions were made (10 - 1
to 10 - 2) using PBS. Twenty microliters was streaked across
a Trypticase Soy Agar (TSA) (Beckton Dickinson Diagnos-
tic Systems, Sparks, MD) plate. The plates were then in-
cubated aerobically at 37°C for 24 hours at which time
the number of colonies was counted. Dilutions with up
to 30 colonies present were used to calculate the median
CFU/pin or CFU/femur. A sample was taken from each me-
dia plate to perform DNase, coagulase, catalase and novo-
biosin tests, in addition to culturing it in specific media to
verify the specificity of colonies similar in shape and color.
2.8. Histopathologic Evaluation
The operated femur from one rat in each group was
used for histopathologic evaluation. The sections were
evaluated by a clinical pathologist who was blinded to the
treatment group. Slices of the same osseous plane were
evaluated based on the following parameters of infection
in accordance with Petty and coworkers (32): 1) abscess for-
mation, 2) sequestrum formation, 3) cortical enlargement,
4) cortical destruction, 5) general impression.
2.9. Statistical Analysis
Based on the results of Lucke’s study (30), difference
and standard deviation of 50000 and 80000 CFU per gram
of bone were assumed for calculating sample size, respec-
tively. In a one-way analysis of variance (ANOVA) study,
sample sizes of eight animals in each group achieved 81%
power to detect the differences among the means versus
the alternative of equal means using an F test with a 0.05
significance level (33).
Kolmogorov-Smirnov test was used to determine if
the data exhibited a normal distribution. The radio-
graphs were scored by two independent orthopaedic sur-
geons anonymously. Intraclass correlation coefficients
(ICC) were calculated to check the inter-observer reliabil-
ity. The radiographic results were averaged and compared
using the repeated measure ANOVA. If there was a miss-
ing follow-up, its value was calculated from the mean of
nearby points. The recovered CFU/pin and CFU/femur were
reported as mean CFU and were compared across all five
groups using the ANOVA, with significance set at P < 0.05.
The distributions of CFU/pin or CFU/femur were compared
for each pair of treatment groups using the Scheffe post-
hoc test with significance set at P < 0.05. All the analyses
were performed using the IBM SPSS Statistics Standard 20.0
(Chicago, IL, USA).
3. Results
3.1. Radiographic Assessment
At the third week postoperatively, the fracture was
most evident in the S. aureus group, followed by the S. au-
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reus + ceftriaxone group, but was only weakly evident in
the control and probiotic groups. The radiographs from
the control group were characterized by callus formation
limited to the fracture site. There was also a periosteal reac-
tion in the control group accompanying the newly formed
bone which represented the continuation of the healing
process. The S. aureus group was characterized by exten-
sive periosteal reaction extending throughout the femoral
length. New bone formation beside the periosteal reac-
tion in the S. aureus group did not bridge the fracture site
and was accompanied by osteolysis along the femur. The
S. aureus + ceftriaxone group was characterized by limited
periosteal reaction along with new bone formation which
bridged the fracture site. The S. aureus + Probiotic once
weekly group was characterized by mild periosteal reac-
tion with new bone formation that bridged the fracture
site. There was no evidence of osteolysis in this group. The
S. aureus + Probiotic twice weekly group was characterized
by minor periosteal reaction and cortical thickening with-
out any evidence of a fracture line (Figure 2).
Intra-class correlation coefficients (ICC) for the inter-
observer reliability of the radiographic scores in weeks
one, two and three were 0.52, 0.45 and 0.59, respectively.
The Kolmogorov-Smirnov test revealed a normal distribu-
tion of this variable (P = 0.2). The radiographic scores at
week one were similar in all of the five treatment groups
(ANOVA, P = 0.62). The repeated measure ANOVA to test
the radiographic scores during the follow-up time be-
tween the intervention groups revealed no significant dif-
ferences throughout the follow-up period (P = 0.179) (Fig-
ure 3).
3.2. Recovery of Bacteria
No bacteria were recovered from rats in the control
group. The ANOVA revealed a significant difference in the
CFU/femur (P < 0.001) and CFU/pin (P = 0.001) across all
five treatment groups. When the results of each arm of the
study were compared pair-wise using the Scheffe post-hoc
test, the CFU/femur was significantly lower in the S. aureus
+ Probiotic twice weekly group in comparison with the S.
aureus (P = 0.008) and the S. aureus + ceftriaxone (P = 0.012)
groups; the CFU/femur was not significantly different be-
tween the S. aureusgroup compared with the S. aureus+ cef-
triaxone group (P = 1.0) and the S. aureus + Probiotic twice
weekly group compared with the S. aureus+ Probiotic once
weekly group (P = 0.8). The CFU/pin results followed a sim-
ilar pattern to CFU/femur. (Figure 4, Table 1)
3.3. Histopathology
The specimen from the control group was character-
ized by the presence of callus. In contrast, the specimen
from the S. aureus group was characterized by active reac-
tive bone and osteoid formation with fibrosis, extending to
the marrow space and the cortex with encasement of callus
including hyaline cartilage. Acute suppurative inflamma-
tion was seen which was enclosed in the reactive changes.
The specimen from the S. aureus + Ceftriaxone group was
characterized by the presence of severe and acute suppu-
rative inflammation plus bone sequestrum (acute suppu-
rative osteomyelitis) extending to the fracture site and the
periosteal surface. There was a narrow rim of callus for-
mation that was composed of hyaline cartilage at the pe-
riphery of the inflammation. The specimens from Pro-
biotic groups were similar to that of S. aureus group ex-
cept for more prominent fracture site callus formation in
the probiotic once weekly group, and prominent bone se-
questrum and infarct in the probiotic twice weekly group.
4. Discussion
The results of the present study revealed that viable
Lactobacillus casei can inhibit acute infection caused by S.
aureus. Although the histopathological deduction is lim-
ited due to inadequate histologic specimens, this assess-
ment revealed that probiotic bacteria may slow down the
healing process, in spite of improving the bacteriologic re-
sults. We could not deduct on the radiographic assessment
due to the lack of significant difference between the inter-
vention groups. This may be due to limited sample size or
low inter-observer ICC. To our knowledge, this is the first
study to demonstrate the administration of a viable pro-
biotic strain through a parenteral route (subperiosteal) in
the in vivo treatment of osteomyelitis.
Hospitals in the Europe link for infection control
through surveillance (HELICS) have reported that 48.6% of
surgical site infection secondary to orthopedic surgery was
due to S. aureus (34). S. aureus adheres to fixation devices
by producing a glycocalyx biofilm around prosthetic ma-
terials and forms large micro-colonies. The biofilm confers
bacterial resistance to antibiotics and ingestion by neu-
trophils (6). Conversely, bone necrosis developing early
in the disease process limits the possibility of eradicat-
ing the pathogen and leads to chronicity (35). Treatment
strategies for osteomyelitis mainly consist of three stages,
firstly antimicrobial agents, secondly surgical techniques
and thirdly amputation (36). A variety of antimicrobial
agents with a different spectrum of action, pharmacoki-
netics and pharmacodynamics have been used in this man-
ner. Due to the physiological and anatomic characteristics
of the bone, antimicrobial therapies are thus suboptimal
in the treatment of osteomyelitis. Surgical techniques, in-
cluding limb salvage, muscle grafts, Ilizarov techniques,
antibiotic coated prostheses and antibiotic bone cement
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Figure 1. Flow Chart of Intervention Groups
Figure 2. Representative Radiographs from a Rat in Each Group at 3 Weeks After
Surgery
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Figure 3. Radiographic Scores at One, Two and Three Weeks After Surgery
have also been applied with varying degrees of success (1,
36).
The definition of a Probiotic is: a live micro-organism
which when administered in adequate amounts confers
a health benefit to the host (FAO/WHO report, October,
2001). There are few studies that have assessed the par-
enteral administration of the probiotic. Sheil studied the
parenteral administration of viable probiotic to alleviate
mice induced colitis and arthritis (37). L. casei is a gram pos-
itive bacillus that ferments carbohydrates mainly to lactic
acid which consequently leads to environmental acidifica-
tion down to a pH of 3.5 (38). There are several hypotheses
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Figure 4. Colony Forming Units (CFU) Recovered from Each Femur and the Intramedullary Pin
regarding the mechanism involved in the inhibition pro-
cess of S. aureus by L. casei. They include environmental
acidification, production of hydrogen peroxide, produc-
tion of bacteriocins and nutritional competition (38). Sad-
owska et al. showed that LAB could inhibit staphylococ-
cal adhesion and slime layer production using bacteriocin
and bacteriocin-like inhibitory substances (24). In addi-
tion, laboratory studies revealed that the acidification of
a growth medium by addition of lactic acid down to pH
4.5, completely inhibits the growth of S. aureus (38). The ra-
tio of S. aureus against LAB is another determinant of the
growth inhibition. Therefore, in media where the S. au-
reus population is larger than LAB, the size of the S. aureus
can reach 1010 CFU/mL (a level at which S. aureus begins en-
terotoxin production and limits its growth). However, for
a S. aureus: LAB ratio of 1/1 and 1/10, maximum population
reached by S. aureus is about 106 and 105 CFU/mL, respec-
tively (38).
Lactic acid bacteria are generally safe with limited clin-
ical infections reported in the humans where LAB were the
causative pathogen (39) and few case reports describe the
isolation of LAB from patients with infective endocardi-
tis, localized infection and septicemia (40, 41). Adams and
Marteau (42) concluded that LAB posed no significant risk
of infection if administered orally. There are few studies on
the parenteral use of probiotic (26, 37, 38, 43). Therefore, ex-
tending LAB safety to parenteral administration needs fur-
ther study.
Our study has some limitations. Our experimental
model does not exactly mirror the clinical scenario. There-
fore, we cannot conclude that probiotic could be a treat-
ment option for implant-related osteomyelitis. Mean-
while, this can be a new branch for potential treatment op-
tion in the future. Due to an executory problem in the radi-
ology department, we could not radiograph one group (S.
aureus + Probiotic twice weekly) in week 2 and, therefore,
inputted the missing data by averaging the radiographs
in weeks 1 and 3. We also could not determine the exact
mechanism of the inhibition of S. aureus by L. casei in vivo
and vitro. In the bacteriologic evaluation, we used selective
media for S. aureus where L. casei could not grow and con-
found the finding. In addition, we performed specificity
tests to validate observed colonies as S. aureus and differ-
entiate them from other similar colonies such as Strepto-
coccus and other strains of Staphylococcus. In the histologic
evaluation, the number of specimen from each interven-
tion group was not adequate for statistical analysis. There-
fore, we narratively described the histologic finding with-
out statistical analysis.
In conclusion, parenteral administration of viable L.
casei inhibits S. aureus-induced osteomyelitis as shown by
bacteriologic analysis, but makes no difference to radio-
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Table 1. P Value of Scheffe Post-Hoc Test Compare CFU/Pin And CFU/Femur in Each Pair of Treatment Groups
Control S. aureus S. aureus + Ceftriaxone S. aureus + OnceWeekly
Probiotic
S. aureus + TwiceWeekly
Probiotic
CFU/Bone
Control - < 0.01* < 0.01* 0.02* 0.23
S. aureus < 0.01* - 1.00 0.12 < 0.01*
S. aureus +ceftriaxone < 0.01* 1.00 - 0.16 0.01*
S. aureus + once weekly
probiotic
0.02* 0.12 0.16 - 0.80
S. aureus + twice weekly
probiotic
0.23 < 0.01* 0.01* 0.8 -
CFU/Pin
Control - 0.01* < 0.01* 0.16 0.87
S. aureus 0.01* - 1.00 0.80 0.12
S. aureus +ceftriaxone < 0.01* 1.00 - 0.75 0.09
S. aureus + once weekly
probiotic
0.16 0.80 0.75 - 0.66
S. aureus + twice weekly
probiotic
0.87 0.12 0.09 0.66 -
logic union rates. This could be the first step in devel-
oping an effective, safe and inexpensive treatment for os-
teomyelitis.
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